Bioventus Focused on Double-Digit Growth and Debt Reduction

Bioventus reported 1Q22 orthopedic sales of $108.3 million, +32.4% compared to 1Q21. The company grew +9% organically for the same period.

Despite the strong quarter, perhaps the most notable news is Bioventus' cancellation of its initial funding plan to acquire CartiHeal. The company plans to evaluate the feasibility of alternate financing...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us